Myriad Genetics, Inc., a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company has developed and plans to develop additional products in six medical specialties, such as oncology, preventive care, urology, dermatology, autoimmune, and neuroscience. Molecular Diagnostic Testing The company’s molecular diagnostic tests are designed to analyze genes, their expression levels and corresponding proteins to assess an individual’s risk for developing disease later in life, diagnose disease, determine a patient’s likelihood of responding to a particular drug, or assess a patient’s risk of disease progression and disease recurrence. The company’s primary molecular diagnostic tests are: myRisk Hereditary Cancer: DNA sequencing test for assessing the risks for hereditary cancers. The company’s myRisk Hereditary Cancer test represents the next generation of its existing hereditary cancer testing franchise, which the company anticipates would eventually replace its current predictive medicine test offerings (BRACAnalysis, BART, Colaris and Colaris AP, and Melaris) with a single test. myRisk Hereditary Cancer is designed to determine a patient’s hereditary cancer risk for breast cancer, ovarian cancer, colon cancer, uterine cancer, melanoma, pancreatic cancer, prostate cancer and gastric cancer. myRisk Hereditary Cancer was initially released through an early access launch that began in 2013. BRACAnalysis: DNA sequencing test for assessing the risk of developing breast and ovarian cancer. The company’s BRACAnalysis test is an analysis of the BRCA1 and BRCA2 genes for assessing a woman’s risk of developing hereditary breast and ovarian cancer. Additionally, BRACAnalysis might be used to assist patients already diagnosed with breast or ovarian cancer and their physicians in determining the appropriate therapeutic interventions to address their disease. BART: DNA sequencing test for hereditary breast and ovarian cancer. The company’s BART test is based on proprietary technology for detecting large genomic rearrangements in the genes involved in hereditary breast and ovarian cancer patients. BRACAnalysis CDx: DNA sequencing test for use as a companion diagnostic with the poly ADP ribose (PARP) inhibitor Lynparza (olaparib) indicated for use in identifying ovarian cancer patients with deleterious or suspected deleterious germline BRCA variants eligible for treatment with Lynparza. Tumor BRACAnalysis CDx: DNA sequencing test designed to be utilized to predict response to DNA damaging agents, such as platinum based chemotherapy agents and poly ADP ribose inhibitors. Tumor BRACAnalysis CDx looks at both germline and somatic mutations in the BRCA1 and BRCA2 genes giving a more complete picture of potential loss of DNA repair ability within the tumor. COLARIS: DNA sequencing test for assessing the risk of colorectal and uterine cancer. The company’s COLARIS test is an analysis of the MLH1, MSH2, MSH6, PMS2, EPCAM, and MYH genes for assessing a person’s risk of developing colorectal and uterine cancer. Colon cancer is a preventable disease if high-risk individuals diligently have colonoscopies and remove any precancerous polyps. COLARIS AP: DNA sequencing test for assessing the risk of colorectal cancer. The company’s COLARIS AP test detects mutations in the APC and MYH genes, which cause a colon polyp-forming syndrome, such as familial adenomatous polyposis (FAP), a more common variation of the syndrome known as attenuated FAP, and the MYH-associated polyposis signature (MAP). Effective preventive measures include colonoscopy and the removal of pre-cancerous polyps and prophylactic surgery. VectraDA: Protein detection test for assessing the disease activity of rheumatoid arthritis (RA). The company’s Vectra DA test is an objective multi-biomarker blood test validated to measure RA disease activity. Vectra DA assesses multiple mechanisms and pathways associated with RA disease activity and integrates the concentrations of 12 serum proteins into a single score reported on a scale of 1 to 100. The test m
myriad genetics inc
(MYD:German Stock Exchange)
320 Wakara Way
Salt Lake City, UT 84108
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content.
|No competitor information is available for MYD.|
|View Industry Companies|
Sponsored Financial Commentaries
To contact MYRIAD GENETICS INC, please visit www.myriad.com. Company data is provided by Capital IQ. Please use this form to report any data issues.